The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Open accessAbstract
Key Points: After hydroxycarbamide therapy in high-risk ET, ruxolitinib showed no improvement for complete or partial response rates compared with BAT. Ruxolitinib significantly improved some disease-related symptoms, but rates of thrombosis, hemorrhage, or transformation were not different.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Self-citationJAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Self-citationDesign Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials
Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., & Smith, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.149 · Cited by 408
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovsek, S., Mesa, R., Kiladjian, J.-J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 566
Self-citationTefferi, A., & Barbui, T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26008 · Cited by 352
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115
Metadata
- Authors
- Harrison, C. N., Mead, A. J., Panchal, A., Fox, S., Yap, C., Gbandi, E., Houlton, A., Alimam, S., Ewing, J., Wood, M., Chen, F., Coppell, J., Panoskaltsis, N., Knapper, S., Ali, S., Hamblin, A., Scherber, R., Dueck, A. C., Cross, N. C. P., Mesa, R., & McMullin, M. F.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-10-26
- Volume
- 130
- Issue
- 17
- Pages
- 1889-1897
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2744415080
- Cited by
- 174
- References
- 4
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. https://app.cochat.ai/papers/10.1182/blood-2017-05-785790
- The paper
- Harrison, C. N., Mead, A. J., Panchal, A., Fox, S., Yap, C., Gbandi, E., Houlton, A., Alimam, S., Ewing, J., Wood, M., Chen, F., Coppell, J., Panoskaltsis, N., Knapper, S., Ali, S., Hamblin, A., Scherber, R., Dueck, A. C., Cross, N. C. P., . . . McMullin, M. F. (2017). Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. https://doi.org/10.1182/blood-2017-05-785790
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.